Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

Tyrosine kinase inhibitors of anaplastic lymphoma kinase (ALK-TKIs) including alectinib have been the standard therapy against ALK fusion gene-positive non–small cell lung cancers (NSCLCs). Many ALK fusion variants have been identified in NSCLCs, and the predominant variants are echinoderm microtubu...

Descripción completa

Detalles Bibliográficos
Autores principales: Furugaki, Koh, Harada, Naoki, Yoshimura, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Pre-Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734629/
https://www.ncbi.nlm.nih.gov/pubmed/34520436
http://dx.doi.org/10.1097/CAD.0000000000001249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734629/
https://www.ncbi.nlm.nih.gov/pubmed/34520436
http://dx.doi.org/10.1097/CAD.0000000000001249

Ejemplares similares